tbuckley/cabot-search huggingface dataset:
Abstract 5285: ADAM12: A novel mediator of tumor angiogenesis
Authors: Roopali Roy, Marsha A. Moses
Journal: Cancer Research (2012)

Abstract ADAM12 (a disintegrin and metalloprotease) is a member of a family of integral membrane and secreted Zn-dependent metalloproteases that have diverse roles in normal and pathological states. Human ADAM12 is expressed as two alternatively spliced forms, a membrane-anchored long form (ADAM12-L), and a short secreted form (ADAM12-S). Increased levels of ADAM12 mRNA and protein have been reported in a variety of cancers including colon, hepatocellular, lung, gastric and glioblastoma. We have previously reported that urinary ADAM12 is predictive of disease status and stage in breast cancer. We have also demonstrated that expression of ADAM12 isoforms in breast tumor cells results in a higher rate of tumor take, increased tumor size and endocrine resistance. ADAM12-S expression stimulated migration and invasion of breast tumor cells in vitro and local and distant tumor invasion in vivo. In the course of these studies, we observed that ADAM12 is upregulated in the vessels of aggressive breast tumors as compared to normal adjacent breast tissue. ADAM12-overexpressing breast tumors also displayed a higher microvascular density. Furthermore, we found that angiogenic tumors express higher levels of ADAM12 compared to their preangiogenic counterparts. The goal of the present study was to determine whether ADAM12 regulates tumor angiogenesis. Basal levels of ADAM12-L expression in HUVEC and HMVEC are relatively low, however, both ADAM12 protein and mRNA expression is significantly increased when cells are stimulated with growth factors such as VEGF, bFGF or inflammatory cytokines such as TNFα, TGFβ or IL1α. Interestingly, VEGF stimulation of endothelial cells (EC) resulted in ADAM12 protein expression and/or localization specifically along the invadopodia of these cells. Consistent with these results, we found that ADAM12 overexpression in EC resulted in significantly increased rates of migration, capillary tube formation and increased adhesion to fibronectin and type IV collagen but not laminin. In vivo studies demonstrate that ADAM12 significantly increases bFGF-mediated angiogenesis in the mouse corneal pocket assay. Taken together, our data provide evidence supporting a novel role for ADAM12 in the regulation of endothelial cell function and tumor angiogenesis. Studies to investigate the mechanism/s by which ADAM12 may regulate angiogenesis are ongoing. [The authors acknowledge the support of NIH PO1 CA045548, The Breast Cancer Research Foundation and The Simeon J. Fortin Foundation] Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5285. doi:1538-7445.AM2012-5285
European and North American scientific meetings under review: presentation and subsequent publication of breast cancer related abstracts in peer-reviewed journals.
Authors: SD Costa, AS Ignatov, J Bischoff, AF Taran
Journal: Cancer Research (2009)

Abstract Abstract #3115 Introduction: The number of scientific meetings with breast cancer-related topics increases constantly and therefore so does the number of presented abstracts. Many of these abstracts are not reported in peer-reviewed journals post-conference. This lack of final publication constitutes a loophole in scientific reporting. Furthermore, it retrospectively assesses the quality of the review process the abstracts undergo prior to the meetings. We critically reviewed the publication rates of breast cancer-related abstracts submitted to the four major oncology meetings for breast cancer in Europe and North America in 2002.&amp;#x2028; Material and methods: The authors identified all breast cancer-related abstracts presented or published at the annual meetings of the ASCO, SABCS, EBCC and ESMO in 2002. First, a MEDLINE search identified the abstracts written by the first, second and last authors that matched a journal article by these authors. Second, the match between the study described in the abstract and full publication was determined.&amp;#x2028; Results: A total number of 1620 abstracts were analyzed.&amp;#x2028; Mean rate of full publication: 44,5%; publication rate of EUR meetings: 33,3%; publication rate of NA meetings: 52,7% (p&amp;lt;0,001). Median time to full publication: 11,55 months (CI 95%;7,58 to 15,66 months; full publication for the EUR meetings: 8,59 months; full publication for the NA meetings: 13,44 months (p&amp;lt;0,001). Median impact factor publishing journals: 1,95 IP (CI 95% 0,9 to 2,77 IP), published abstracts of the EUR meetings: 1,09; published abstracts of the NA meetings: 2,5(p&amp;lt;0,001). Estimated probability for an abstract not to be published after 60 months: 55,5%; abstract of the EUR meetings: 67,5%; abstract of the NA meetings: 47,8%(p&amp;lt;0,001) (Figure).&amp;#x2028; Discussion: We found that only about half of all studies first presented as abstracts at major meetings were published as full papers later. Thus, those who rely on scientific evidence to make health care decisions are faced with a biased subset of scientific evidence. It is clear that full-paper reviewing in peer-reviewed journals is more complex and increases the scientific value of a paper in comparison to a meeting abstract. In the past few years the number of scientific meetings on breast cancer and the number of participants attending those has increased dramatically. Our study demonstrated that this does not imply for the quality of the presented data. We propose that scientists who publish their work in peer-reviewed journals should avoid citation of abstracts and/or talks presented even at major international meetings because they risk to rely on data that has not between reviewed thoroughly enough.&amp;#x2028; &amp;#x2028; Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3115.
Acute-Phase Proteins and Other Systemic Responses to Inflammation
Authors: Cem Gabay, Irving Kushner
Journal: New England Journal of Medicine (1999)

A large number of changes, distant from the site or sites of inflammation and involving many organ systems, may accompany inflammation. In 1930 interest was focused on these changes by the discovery of C-reactive protein (so named because it reacted with the pneumococcal C-polysaccharide) in the plasma of patients during the acute phase of pneumococcal pneumonia.1 Accordingly, these systemic changes have since been referred to as the acute-phase response,2 even though they accompany both acute and chronic inflammatory disorders. New acute-phase phenomena continue to be recognized, and the mechanisms mediating them are becoming better understood. This review summarizes much of . . .
Colonic perforation caused by the inadvertent trapping of mucosa in a retrieval net
Authors: Roberto Di Mitri, Filippo Mocciaro, Sandro Sferrazza, Rosalba Orlando, Vincenzo Costanza
Journal: Endoscopy (2014)

Colonoscopy is a common procedure for the diagnosis and treatment of a wide range of conditions [1]. Serious complications are uncommon with a pooled overall serious adverse event rate of 2.8 per 1000 procedures.
Belatacept and Long-Term Outcomes in Kidney Transplantation
Authors: Flavio Vincenti, Lionel Rostaing, Joseph Grinyo, Kim Rice, Steven Steinberg, Luis Gaite, Marie-Christine Moal, Guillermo A. Mondragon-Ramirez, Jatin Kothari, Martin S. Polinsky, Herwig-Ulf Meier-Kriesche, Stephane Munier, Christian P. Larsen
Journal: New England Journal of Medicine (2016)

In previous analyses of BENEFIT, a phase 3 study, belatacept-based immunosuppression, as compared with cyclosporine-based immunosuppression, was associated with similar patient and graft survival and significantly improved renal function in kidney-transplant recipients. Here we present the final results from this study.We randomly assigned kidney-transplant recipients to a more-intensive belatacept regimen, a less-intensive belatacept regimen, or a cyclosporine regimen. Efficacy and safety outcomes for all patients who underwent randomization and transplantation were analyzed at year 7 (month 84).A total of 666 participants were randomly assigned to a study group and underwent transplantation. Of the 660 patients who were treated, 153 of the 219 patients treated with the more-intensive belatacept regimen, 163 of the 226 treated with the less-intensive belatacept regimen, and 131 of the 215 treated with the cyclosporine regimen were followed for the full 84-month period; all available data were used in the analysis. A 43% reduction in the risk of death or graft loss was observed for both the more-intensive and the less-intensive belatacept regimens as compared with the cyclosporine regimen (hazard ratio with the more-intensive regimen, 0.57; 95% confidence interval [CI], 0.35 to 0.95; P=0.02; hazard ratio with the less-intensive regimen, 0.57; 95% CI, 0.35 to 0.94; P=0.02), with equal contributions from the lower rates of death and graft loss. The mean estimated glomerular filtration rate (eGFR) increased over the 7-year period with both belatacept regimens but declined with the cyclosporine regimen. The cumulative frequencies of serious adverse events at month 84 were similar across treatment groups.Seven years after transplantation, patient and graft survival and the mean eGFR were significantly higher with belatacept (both the more-intensive regimen and the less-intensive regimen) than with cyclosporine. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00256750.).
Abstract P4-14-10: Atypical Ductal Hyperplasia diagnosed on directional vacuum-assisted biopsy: is surgical excision mandatory?
Authors: M-P Chauvet, G Rivaux, I Farre, J-L Houpeau, S Giard, L Ceugnart
Journal: Cancer Research (2012)

Abstract Background: The incidence of atypical ductal hyperplasia (ADH) is increasing due to mass screening. Because of the underestimation risk of malignancy, the management remains controversial. Our goal was to analyze clinicopathologic features of patients with ADH diagnosed on directional vacuum-assisted biopsy (DVAB). The objectives of this continuous retrospective study were to evaluate the underestimation rate of malignancy and to identify predictors of upgrade to carcinoma. Methods: Between 2003 and 2010, 3159 patients underwent stereotactic DVAB in our institute. We retrospectively evaluate clinical, mammographic and pathological features of 298 cases of ADH who underwent surgical excision in our center (93.1%). Patients with concurrent history of breast cancer, intraductal carcinoma (DCIS) associated, or with no follow-up or surgical excision on place were excluded. Histological scar of macrobiopsy was systematically searched in surgical specimens. A pathologic upgrade was defined by presence of invasive cancer or DCIS on surgical specimen. Statistical tests used were the chi-square or Fisher's exact test. Results: Among the 298 studied DVAB, 224 ADH were isolated (75.2%), 46 associated to flat epithelial atypia (15.4%) and 28 to lobular neoplasia (9.4%). 98.4% patients presented microcalcifications at diagnosis. In 52 cases, lesions were upgraded to DCIS (n = 38) or invasive cancer (n = 14). The underestimated rate was 17.5%. In 67.3% cases, upgrade lesions were low or intermediate grade DCIS. Only the history of contralateral breast cancer was significantly correlated with the underestimated rate (p = 0.04). There was no statistical difference between these 52 cases and the 246 others for: family history, size of calcification, sampling number, histological lesion, and quality of calcifications removal. Conclusions: In this study, DVAB may not be considered a therapeutic procedure in case of ADH, even in the case of complete removal of microcalcifications. It is still challenging to identify a subgroup of ADH cases with a low upgrade rate. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-14-10.
S112 Mmp12 And Lmo7 Are Key Genes Involved In The Early Pathogenesis Of Squamous Cell Carcinoma Of The Lung
Authors: V. Teixeira, S. Lourenco, M. Falzon, A. Capitanio, S. Bottoms, B. Carroll, J. Brown, J. George, S. Janes
Journal: Thorax (2014)

<h3></h3> Lung cancer is the most lethal cancer type worldwide. In order to improve patient survival it is important to enhance our understanding of the early changes associated with lung cancer progression. UCLH has a unique cohort of patients with pre-invasive lung squamous cell carcinoma (SCC) lesions. Within this cohort there is a discrepancy between the prevalence of pre-invasive lesions and the incidence of invasive lung cancer, which suggests that not all pre-invasive lesions progress to invasive carcinomas. The aim of this study was to identify and characterise key genes involved in the early pathogenesis of lung SCC. We performed genome-wide gene expression Illumina Whole-Genome DASL® arrays in 19 regressive and 20 progressive pre-invasive lung SCC lesions. The expression of matrix metallopeptidase 12 (MMP12) and LIM domain 7 (LMO7) was also determined in the 39 pre-invasive lung cancer lesions by immunostaining analysis. The functional role of MMP12 and LMO7 in cell migration and invasion was demonstrated by MMP12 and LMO7-knockdown in different squamous cell carcinoma cell lines and human bronchial epithelial cells (HBECs), respectively. We found 939 genes significantly differently expressed between the progressive and the regressive pre-invasive lung SCC lesions. We identified a remarkably elevated expression of a spectrum of genes in the progressive lung SCC lesions involved in different related cancer pathways including chromosome instability, p53 signalling and Wnt/β-catenin signalling. MMP12 and LMO7 were found within the highest significantly differently expressed genes and were therefore chosen to pursue studies focused on understanding the potential mechanisms leading to the development of lung SCC. In agreement with the gene expression data the expression of MMP12 and LMO7 proteins were up-regulated and down-regulated, respectively, in progressive when compared with regressive lesions. Inhibiting MMP12 by MMP12 knockdown significantly reduced the migration and invasion of different squamous cell carcinoma cell lines (A431, H357 and H376). We also established HBECs knockdown targeting LMO7. We observed a significant increase in the migration and invasion of HBECs cells in the LMO7 shRNA knockdown compared to control. Our results suggest that MMP12 and LMO7 may be potential therapeutic markers for lung cancer at early stage.
Dangers Seen in Increased Treatment Of Elderly
Authors: E. Blume
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Dangers Seen in Increased Treatment Of Elderly Get access Elaine Blume Elaine Blume Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 18, 16 September 1992, Pages 1394–1397, https://doi.org/10.1093/jnci/84.18.1394 Published: 16 September 1992
FACTORES RELACIONADOS CON LA COLONOSCOPIA INCOMPLETA: PAPEL DE LA COLONOGRAFIA POR TOMOGRAFIA COMPUTERIZADA (TC) COMO PRUEBA COMPLEMENTARIA A LA COLONOSCOPIA CONVENCIONAL
Authors: VJ Morales Alvarado, P Latorre Año, B Solaz Garrido, A Lopez Serrano, J Martinez Perez Maria, I Ortiz Polo, M Paredes Arquiola Jose, G Vidal Iniesta, I Ferrando Marrades, MD Anton Conejero, E Moreno-Osset
Journal: Endoscopy (2013)

Introducción: La colonoscopia tiene un importante papel en la detección del cáncer colorrectal (CCR). El fracaso en la intubación cecal acontece entre 2 – 23% de las colonoscopias. La Colonografía por TC (CTC) puede permitir la completa exploración del colon, conocer con más precisión la causa de colonoscopia incompleta (CI) y valorar posibles lesiones significativas en el tramo de colon no explorado. Objetivo: Identificar causas de CI y describir el tipo de lesiones encontradas en el colon mediante el uso de CTC, así como su seguridad. Material y Método: Estudio descriptivo retrospectivo de casos con CI y a los que se realizó una CTC posterior. Se obtuvieron datos de la historia clínica y de las bases de datos del Área de Endoscopias y del Servicio de Radiología. Resultados: Desde Enero-2010 hasta Abril-2013 se incluyeron 105 pacientes: 63 hombres (60,0%) y 42 mujeres (40,0%); edad media 66,8 (límites: 39 – 89) años. El 38,1% tenían antecedentes de cirugía abdominal, el 17,1% cirugía ginecológica. Principales indicaciones de colonoscopia: sospecha de CCR (33,3%), hemorragia digestiva baja (20,4%) y anemia ferropénica (11,1%). El tramo más proximal explorado por la colonoscopia fue: recto (9,5%), sigma (50,5%), colon descendente (12,4%), ángulo esplénico (3,8%), colon transverso (10,5%), ángulo hepático (9,5%) y colon ascendente (3,8%). Causas frecuentes de CI: CCR obstructivo (52,8%), estenosis benigna (9,4%) principalmente secundaria a diverticulitis (6,6%), y factores anatómicos (8,5%). Lesiones detectadas en la CTC: pólipos (34,7%), lesiones estenosantes malignas (28,5%), diverticulosis (9,5%) y lesiones estenosantes benignas (4,5%). En 2 pacientes (1,9%) se detectó CCR en el tramo no explorado por la colonoscopia convencional. Conclusiones: La causa más frecuente de CI fue CCR obstructivo. La CTC es una herramienta útil y segura para completar el estudio del colon en pacientes con CI previa. La CTC detecta lesiones clínicamente importantes que pueden modificar el plan quirúrgico del paciente.
Abstract LB-441: Mutation in SLX4 gen in a multiple case breast cancer family
Authors: Gorka Ruiz de Garibay Ponce, María Avellaneda Díaz, Belén Gaviña, Pedro Perez-Segura, Eduardo Díaz-Rubio, Trinidad Caldés, Miguel de la Hoya
Journal: Cancer Research (2012)

Abstract Fanconi Anemia (FA) is a genetically heterogeneous, rare autosomal recessive disorder characterized by development abnormalities, bone marrow failure, and childhood cancers. Over the past few years, a common genetic basis for FA and breast and/or ovarian cancer susceptibility has been uncovered. In particular, BRCA2 (FANCD1), BRIP1 (also known as BACH1 and FANCJ), PALB2 (FANCN), and RAD51C germ-line mutations have been found to lead both to FA (when biallelic) and to increased breast and/or ovarian cancer risk (when monoallelic). Recently, two studies demonstrated that biallelic germ-line mutations in SLX4, which encodes an endonuclease, cause a previously unknown FA subtype (FA-P). Therefore, SLX4 should be considered a bona fide candidate gene for breast cancer susceptibility, as suggested in both studies. We have screened 347 non-BRCA1/BRCA2 index cases from multiple case breast and/or ovarian cancer families for point mutations in the SLX4 gene. The whole coding sequence and flanking intronic regions were analyzed using High Resolution Melting (HRM) analysis followed by direct sequencing of abnormal melting curve samples. An SLX4 missense change in c.1114C&amp;gt;T (p.Arg372Trp) was detected in a family with four cases of breast cancer in two generations. This mutation segregates with disease within the family and is not present in the dbSNP (build 34). Polyphen-2 and SIFT in silico analysis tools predict a deleterious effect on protein structure and multiple alignment within orthologous proteins suggests a high degree of conservation. Previous studies in FA patients have identified two different splicing mutations (c.1163+2T&amp;gt;A and c.1163+3dupT) that cause in frame exon 5 skipping. The resulting protein (p.Arg317_Phe387del) lacks two repeated UBZ4 domains known to interact with other endonucleases, mismatch repair proteins, and ubiquitin. It has been suggested that UBZ4 may be involved in targeting SLX4 to sites of DNA damage by binding to ubiquitinated proteins. The missense change we have found introduces a highly hydrophobic amino acid within the same region, which could affect the folding of the UBZ4 domain or disrupt a specific protein-protein interaction. Our study supports a role for SLX4 in breast cancer susceptibility. Further studies performed in larger cohorts will be necessary to determine the prevalence of SLX4 mutations among breast cancer risk factors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-441. doi:1538-7445.AM2012-LB-441
Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Metastatic Differentiated Thyroid Cancers
Authors: Soizic Masson-Deshayes, Claire Schvartz, Cécile Dalban, Sofiane Guendouzen, Jean-Marie Pochart, Audrey Dalac, Sandrine Fieffe, Claire Bruna-Muraille, Tienhan Sandrine Dabakuyo-Yonli, Dimitri Papathanassiou
Journal: Clinical Nuclear Medicine (2015)

Purpose To evaluate the prognostic value of 18F-fluorodeoxyglucose positron emission tomography (FDG PET) with quantitative analysis using metabolic parameters in metastatic differentiated thyroid cancer (DTC). Materials and Methods The FDG-PET scans of 37 patients with metastatic DTC were studied retrospectively. The number of FDG-avid lesions, the SUVmax, the SULpeak of the lesion with the highest FDG uptake, the overall metabolic tumor volume (MTV), and the total lesion glycolysis (TLG) were measured. Curves of progression-free survival (Kaplan-Meier) and Cox univariate and multivariate analyses determined the prognostic factors for survival. Results Progression-free survival was better in patients with less than 10 FDG-avid lesions (P = 0.0089), the SUVmax less than 10 (P = 0.0026), the SULpeak less than 5 (P = 0.0004), and the TLG less than 154 (P = 0.0110). Cox analyses showed that only the result of the PET scan was predictive of survival (age, TNM stage, histology, and the 131I whole body radioiodine scan were not associated with prognosis). In the univariate analysis, prognostic factors for progression-free survival and overall survival were the SUVmax (P = 0.004; P = 0.018), the SULpeak (P = 0.001; P = 0.017), and the TLG (P = 0.014; P = 0.012). The number of FDG-avid lesions was significantly associated with progression-free survival (P = 0.012), but not the MTV. In the multivariate analysis, the number of FDG-avid lesions and the SULpeak were independent prognostic factors. Conclusions FDG PET using metabolic parameters is a prognostic factor in metastatic DTC. It could improve the therapeutic management and follow-up of patients.
Esophagogastrectomy Producing An Unusual Appearance on Lung Imaging
Authors: DEO GALEON RELIGIOSO, HENRY YEUNG, ABDELHAMID H. ELGAZZAR
Journal: Clinical Nuclear Medicine (1996)

Although serendipitous findings on scintigraphic studles may be diagnostically valuable and cannot be ignored, they may be confusing. The authors present a case of a patient who had an esophageal stricture treated surgically by esophagogastrectomy. The stomach was surgically pulled up into an intrathoracic position and anastomosed to the proximal esophagus. Tc-99m DTPA activity from a pre-perfusion ventilation study in the supradiaphragmatic stomach caused an unusual appearance on the subsequent Tc-99m MAA perfusion scan. This finding can be diagnostically confusing and familiarity with anatomical changes is essential to explain it.
Wadi Yusuf Nassar
Authors: P. H. Jones
Journal: BMJ (2011)

Wadi Yusuf Nassar, died in Wythenshawe Hospital after a sudden and unexpected deterioration in his health, having had prostatic cancer for some time. He was born in Jifna, a small village near Jerusalem, the son of a priest in the Greek Orthodox Church, on 2 March 1932 and educated in Jerusalem at Rashidya College and later at Birzeit College. He graduated MD at the American University of Beirut in 1956 and joined the Jordanian Army as a major, commanded the 4th field ambulance unit, and was head of the medical support unit for the filming of Lawrence of Arabia , starring Peter O’Toole.

He came to England to train in ear, nose, …